128 related articles for article (PubMed ID: 31790621)
21. Strong correlation between molecular changes in endometrial carcinomas and concomitant hyperplasia.
Zauber P; Denehy TR; Taylor RR; Ongcapin EH; Marotta S; Sabbath-Solitare M
Int J Gynecol Cancer; 2015 Jun; 25(5):863-8. PubMed ID: 25768080
[TBL] [Abstract][Full Text] [Related]
22. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
[TBL] [Abstract][Full Text] [Related]
23. Early-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence.
Imboden S; Tapia C; Scheiwiller N; Kocbek V; Altermatt HJ; Janzen J; Mueller MD; McKinnon B
Acta Obstet Gynecol Scand; 2020 Feb; 99(2):196-203. PubMed ID: 31562818
[TBL] [Abstract][Full Text] [Related]
24. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer.
Ikeda Y; Oda K; Nakagawa S; Murayama-Hosokawa S; Yamamoto S; Ishikawa S; Wang L; Takazawa Y; Maeda D; Wada-Hiraike O; Kawana K; Fukayama M; Aburatani H; Yano T; Kozuma S; Taketani Y
Int J Gynecol Cancer; 2012 Jun; 22(5):725-31. PubMed ID: 22635024
[TBL] [Abstract][Full Text] [Related]
25. Chromosome aberrations [dup(1q)] in endometrial cancer: Gene analysis of 54 surgical specimens in Turkey.
Sever E; Döğer E; Kumbasar S; Şık BA; Temur M; Yılmaz HT; Yılmaz Ö; Özbay PO; Yücesoy İ
Taiwan J Obstet Gynecol; 2016 Jun; 55(3):357-62. PubMed ID: 27343315
[TBL] [Abstract][Full Text] [Related]
26. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
27. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
[TBL] [Abstract][Full Text] [Related]
28. [KRAS mutations analysis in mucinous epithelial lesions of the endometrium].
Zheng XZ; Zhan Y; Ma JH; Xu HW; Zhi WX; Chen TB; Qin XY; Wang P; Zhang LH; Gu YC; Jin YL; Zhu L; Wu BQ
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):687-690. PubMed ID: 30220122
[No Abstract] [Full Text] [Related]
29. Impact of 3'UTR variation patterns of the KRAS gene on the aggressiveness of pancreatobiliary tumors with the KRAS G13D mutation in a Turkish population.
Egeli U; Ak S; Cecener G; Tunca B; Tezcan G; Sevinc ED; Kaya E; Dundar HZ; Sarkut P; Ozen Y; Balcin O; Evrensel T; Yerci O; Ugras N
Pancreatology; 2016; 16(4):677-86. PubMed ID: 27256640
[TBL] [Abstract][Full Text] [Related]
30. The impact of uterine adenomyosis on the histopathological risk factors and survival in patients with endometrial adenocarcinoma.
Yetimalar MH; Kilic D; Bezircioglu I; Yigit S
J Obstet Gynaecol; 2022 Aug; 42(6):2213-2219. PubMed ID: 35260040
[TBL] [Abstract][Full Text] [Related]
31. Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer.
Huang X; Yang Y; Guo Y; Cao ZL; Cui ZW; Hu TC; Gao LB
Genet Mol Res; 2015 Dec; 14(4):16913-20. PubMed ID: 26681038
[TBL] [Abstract][Full Text] [Related]
32. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.
Kundu ST; Nallur S; Paranjape T; Boeke M; Weidhaas JB; Slack FJ
Cell Cycle; 2012 Jan; 11(2):361-6. PubMed ID: 22189714
[TBL] [Abstract][Full Text] [Related]
33. Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer.
Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklinska W; Chyczewski L; Kulikowski M
Int J Cancer; 2010 Aug; 127(3):612-21. PubMed ID: 19960433
[TBL] [Abstract][Full Text] [Related]
34. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM
Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484
[TBL] [Abstract][Full Text] [Related]
35. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
36. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.
Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(1):65-8. PubMed ID: 19419940
[TBL] [Abstract][Full Text] [Related]
37. Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis.
Alexander-Sefre F; Salvesen HB; Ryan A; Singh N; Akslen LA; MacDonald N; Wilbanks G; Jacobs IJ
Gynecol Oncol; 2003 Oct; 91(1):218-25. PubMed ID: 14529685
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological Characteristics and
Sung JY; Jung YY; Kim HS
Anticancer Res; 2018 May; 38(5):2779-2786. PubMed ID: 29715099
[TBL] [Abstract][Full Text] [Related]
39. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T
Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323
[TBL] [Abstract][Full Text] [Related]
40. Sperm-associated antigen 9 is a promising marker for early diagnosis of endometrial cancer.
Baser E; Togrul C; Ozgu E; Ayhan S; Caglar M; Erkaya S; Gungor T
Asian Pac J Cancer Prev; 2013; 14(12):7635-8. PubMed ID: 24460345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]